Fidelity Investments’s Baudax Bio, Inc. Common Stock BXRX Stock Holding History

Fidelity Investments’s Portfolio BXRX Stock Details BXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,056	Closed	-$1.79K	–	5702
2023 Q1	$1.79K	Buy	+1,056	New	+$2.69K	﹤0.01%	4649
2022 Q1	–	Sell	-1	Closed	–	–	5724
2021 Q4	$0	Buy	+1	New	+$627	﹤0.01%	5195
2021 Q3	–	Hold	0	–	–	–	5325
2021 Q2	–	Hold	0	–	–	–	5149

Other funds holding BXRX

Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Fidelity Investments's BXRX Position: Q2 2023 in Review

Fidelity Investments sold out of Baudax Bio, Inc. Common Stock (BXRX) in Q2 2023, closing a stake of 1,056 shares — an estimated $1.79K sold.

Fidelity Investments first reported a position in BXRX in Q4 2021 and held it in 2 quarters. The position peaked at $1.79K in Q1 2023. 12 funds tracked by Wall St. Rank hold BXRX as of Q2 2023.

Fidelity Investments reported no remaining Baudax Bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Fidelity Investments sold 1,056 Baudax Bio, Inc. Common Stock shares in Q2 2023, an estimated $1.79K.
Fidelity Investments first reported a position in Baudax Bio, Inc. Common Stock in Q4 2021 and held it in 2 quarters.
Fidelity Investments's Baudax Bio, Inc. Common Stock position peaked at $1.79K in Q1 2023.
12 funds tracked by Wall St. Rank held Baudax Bio, Inc. Common Stock as of Q2 2023.

Based on Fidelity Investments's 13F filing for Q2 2023, filed 11 Aug 2023.